Eastern Michigan University
Approval of new drugs by the U. S. Food and Drug Administration: Problems with the process and access to unapproved drugs
Abstract
dc:description.abstract<p>Today, the vast majority of drugs available for patient use have gone through a rigorous system of human clinical trials supervised by the Food and Drug Administration (FDA), to ensure the drugs are safe and efficacious. There are now citizen advocacy groups that seek use of drugs not yet approved by the FDA, to be administered to terminally ill patients who have exhausted all other available means of therapy. The FDA has programs for terminal patients, under the supervision of their physicians, to use unapproved drugs; however, the advocacy groups seek access to drugs in much earlier phases than is now allowed, raising serious safety concerns for patients. Use of drugs outside of the clinical trials system undermines the integrity of the FDA’s drug development process by slowing enrollment, which in turn slows approval and timely access of safe and efficacious drugs to all of society.</p>
Degree
thesis:*- Name thesis:degree_name
- Master of Science (MS)
- Level thesis:degree_level
- Open Access Thesis
- Discipline thesis:degree_discipline
- Health Sciences
- Year
- 2007
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Hoeft-Loyer, Christine M
- Contributors dc:contributor
-
- Stephen Sonstein, PhD
Subjects
dc:subject × 7Identifiers
dc:identifier.*- Repository record dc:identifier
- https://commons.emich.edu/theses/15
- OAI identifier oai:identifier
- oai:commons.emich.edu:theses-1014